Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

Phase 3positiveIvonescimabPositive

AI Analysis

Summary

Ivonescimab combined with chemotherapy demonstrated consistent, favorable overall survival results in an updated analysis of the global Phase III HARMONi study across Western and Asian patient populations.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Updated analysis from global Phase III HARMONi study shows consistent, favorable overall survival results in both Western and Asian patients

Importance:7/10

Sentiment:

0.70

Phase 3 trialOncologyGlobal studyOverall survivalChemotherapy combination

Related Companies

$SMMT

Read the original article

Published by yahoo_finance on July 22, 2026 10:30 AM

Read Original